Seasonal influenza virus vaccine intradermal - Sanofi
Alternative Names: Flu-ID; Fluzone ID; IDflu; Intanza; Intradermic influenza vaccine - sanofi aventis; Intradermic influenza vaccine - sanofi pasteurLatest Information Update: 07 Jul 2022
Price :
$50 *
At a glance
- Originator sanofi pasteur
- Developer Sanofi Pasteur
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Influenza virus infections
Most Recent Events
- 01 Jul 2022 US FDA approves intradermal seasonal influenza virus vaccine for 2022-2023 flu season for the treatment of influenza virus infections
- 07 Sep 2021 Discontinued - Phase-III for Influenza virus infections (Prevention) in Puerto Rico (Intradermal)
- 01 Oct 2014 Sanofi Pasteur initiates enrolment in a phase IV trial for Influenza virus infections (Prevention, 2014-2015 season) in USA (NCT02258334)